SEARCH

SEARCH BY CITATION

References

  • 1
    Johanson GA: Symptom character and prevalence during cancer patients' last days of life. Am J Hosp Palliat Care 1991; 8 (2): 68, 18.
  • 2
    Bonica JJ, Ventafridda V, Twycross RG: Cancer pain, in BonicaJJ (ed): The Management of Pain, ed 2. Philadelphia, Lea & Febiger, 1990, pp 400460.
  • 3
    Coyle N, Adelhardt J, Foley KM, Portenoy RK: Character of terminal illness in the advanced cancer patient: Pain and other symptoms during last four weeks of life. Journal of Pain and Symptom Management 1990; 5: 8393.
  • 4
    Portenoy RK, Miransky J, Thaler HT, et al: Pain in ambulatory patients with lung or colon cancer: Prevalence, characteristics, and effect. Cancer 1992; 70: 16161624.
  • 5
    Twycross RG, Fairfield S: Pain in far-advanced cancer. Pain 1982; 14: 303310.
  • 6
    Brescia FJ, Adler D, Gray G, et al: Hospitalized advanced cancer patients: a profile. Journal of Pain and Symptom Management 1990; 5: 221227.
  • 7
    Ventafridda V, Ripamonti C, De Conno F, et al: Symptom prevalence and control during cancer patients' last days of life. J Palliat Care 1990; 6: 711.
  • 8
    Massie MJ, Holland JC: The cancer patient with pain: Psychiatric complications and their management. Med Clin North Am 1987; 71: 243258.
  • 9
    Cleeland CS: The impact of pain on the patient with cancer. Cancer 1984; 54: 26352641.
  • 10
    Ventafridda V, De Conno F, Ripamonti C, et al: Quality-of-life assessment during a palliative care programme. Ann Oncol 1990; 1: 415420.
  • 11
    Cleeland C: Research in cancer pain: What we know and what we need to know. Cancer 1991; 67: 823827.
  • 12
    Von Roenn JH, Cleeland CS, Gonin R, et al: Physician's attitudes and practice in cancer pain management: A survey from the Eastern Cooperative Oncology Group. Ann Intern Med 1993; 119: 121126.
  • 13
    Portenoy RK: Inadequate outcome of opioid therapy for cancer pain: Influences on practitioners and patients, in PattRB (ed) Cancer Pain, ed 1. Philadelphia, JB Lippincott, 1993, pp 119128.
  • 14
    Cleeland CS, Cleeland LM, Dar R, Rinehardt LC: Factors influencing physician management of cancer pain. Cancer 1986; 58: 796800.
  • 15
    Cleeland CS: Clinical cancer: 31. Barriers to the management of cancer pain: The roles of patient and family. Wis Med J 1988; 87 (11): 135.
  • 16
    Ward SE, Goldberg N, Miller-McCauley V, et al: Patient-related barriers to management of cancer pain. Pain 1993; 52: 319324.
  • 17
    Grossman SA, Sheidler VR, Swedeen K, et al: Correlation of patient and caregiver ratings of cancer pain. Journal of Pain and Symptom Management 1991; 6: 5357.
  • 18
    Weissman DE, Gutmann M, Dahl JL: Physician cancer pain education: A report from the Wisconsin Cancer Pain Initiative. Journal of Pain and Symptom Management 1991; 6: 445448.
  • 19
    Cleeland CS: Pain control: Public and physician's attitudes, in HillCSJr, FieldsWS (eds): Drug Treatment of Cancer Pain in a Drug-Oriented Society. New York, Raven Press, 1989, pp 8189. Advances in Pain Research and Therapy; vol 11.
  • 20
    MacDonald N: Oncology and palliative care: The case for co-ordination. Cancer Treat Rev 1993; 19 (suppl A): 2941.
  • 21
    American Society of Clinical Oncology Ad Hoc Committee on Cancer Pain: Cancer pain assessment and treatment curriculum guidelines. J Clin Oncol 1992; 10: 19761982.
  • 22
    Cherny NI, Portenoy RK: Cancer Pain: Principles of assessment and syndromes, in WallPD, MelzackR (eds): Textbook of Pain, ed 3. Edinburgh: Churchill Livingstone, 1994, pp 787823.
  • 23
    Cleeland CS, Gonin R, Hatfield A, et al: Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994; 330: 592596.
  • 24
    Baillie L: A review of pain assessment tools. Nurs Stand 1993; 7: 2529.
  • 25
    Jensen MP, Karoly P: Measurement of cancer pain by self report, in ChapmanCR, FoleyKM (eds): Current and Emerging Issues in Cancer Pain: Research and Practice. New York, Raven Press, 1993, pp 193218.
  • 26
    Agency for Health Care Policy and Research. Cancer Pain Management Panel: Management of Cancer Pain. Washington, DC, U.S. Dept. of Health and Human Services, 1994. Clinical Practice Guideline Number 9.
  • 27
    Grossman SA, Sheidler VR, McGuire DB, et al: A comparison of the Hopkins Pain Rating Instrument with standard visual analogue and verbal descriptor scales in patients with cancer pain. Journal of Pain and Symptom Management 1992; 7: 196203.
  • 28
    Fishman B, Pasternak S, Wallenstein SL, et al: The Memorial Pain Assessment Card: A valid instrument for the evaluation of cancer pain. Cancer 1987; 60: 11511158.
  • 29
    Daut RL, Cleeland CS, Flanery RC: Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 1983; 17: 197210.
  • 30
    McCaffery M, Ferrell BR: How vital are vital signs?. Nursing 1992; 22: 4246.
  • 31
    American Pain Society Committee of Quality Assurance Standards: American Pain Society quality assurance standards for the relief of acute pain and cancer pain, in BondMR, CharltonJE, WoolfCJ (eds): Proceedings of the VIth World Congress on Pain. Amsterdam, Elsevier 1991, pp 185190. Pain Research and Clinical Management; vol 4.
  • 32
    Willis WD: Mechanisms of somatic pain, in ChapmanCR, FoleyKM (eds): Current and Emerging Issues in Cancer Pain: Research and Practice. New York, Raven Press, 1993, pp 6781.
  • 33
    Gebhart GF: Visceral pain mechanisms, in ChapmanCR, FoleyKM (eds): Current an Emerging Isuues in Cancer Pain: Research and Practice. New York, Raven Press, 1993, pp 99111.
  • 34
    Melzack R, Wall PD: Pain mechanisms: A new theory. Science 1965; 150: 971979.
  • 35
    Basbaum AI, Fields HL: Endogenous pain control systems: Brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci 1984; 7: 309338.
  • 36
    Duggan AW, Weihe E: Central transmission of impulses in nociceptors: Events in the superficial dorsal horn, in BasbaumAI, BessonJM (eds): Towards a New Pharmacotherapy of Pain. New York, John Wiley & Sons, 1991, pp 3567.
  • 37
    Evans CJ, Hammond DL, Fredrickson RCA: The opioid peptides, in PasternakGW (ed): The Opiate Receptors. Clifton, NJ, Humana Press, 1988, pp 2374.
  • 38
    Dickenson AH: Mechanisms of the analgesic actions of opiates and opioids. Br Med Bull 1991; 47: 690702.
  • 39
    International Association for the Study of Pain. Subcommittee on Taxonomy: Pain Terms: A list with definitions and notes on usage. Pain 1980; 8: 249252.
  • 40
    Gonzales GR, Elliot KJ, Portenoy RK, Foley KM: The impact of a comprehensive evaluation in the management of cancer pain. Pain 1991; 47: 141144.
  • 41
    Ventafridda V: Continuing care: A major issue in cancer pain management. Pain 1989; 36: 137143.
  • 42
    World Health Organization: Cancer Pain Relief and Palliative Care: Report of a WHO expert committee. WHO Tech Rep Ser 1990; 804: 175.
  • 43
    Banning A, Sjogren P, Henriksen H: Pain causes in 200 patients referred to a multidisciplinary cancer pain clinic. Pain 1991; 45: 4548.
  • 44
    Foley KM: Clinical assessment of cancer pain. Acta Anaesthesiol Scand 1982; 74 (supp): 9196.
  • 45
    Twycross RG, Lack SA: Symptom control in far advanced cancer: Pain relief. London, Pitman Publishng, 1983.
  • 46
    Cherny NI, Portenoy RK: Practical issues in the management of cancer pain, in WallPD, MelzackR (eds): Textbook of Pain, ed 3. Edinburgh, Churchill Livingstone, 1994, pp 14371467.
  • 47
    Kellgren JG: On the distribution of pain arising from deep somatic structures with charts of segmental pain areas. Clinical Science 1939; 4: 3546.
  • 48
    Ness TJ, Gebhart GF: Visceral pain: A review of experimental studies. Pain 1990; 41: 167234.
  • 49
    Torebjork HE, Ochoa JL, Schady W: Referred pain from intraneural stimulation of muscle fascicles in the median nerve. Pain 1984; 18: 145156.
  • 50
    McCaffery M, Thorpe DM: Differences in perception of pain and the development of adversarial relationships among health care providers, in HillCSJr, FieldsWS (eds): Drug Treatment of Cancer Pain in a Drug-Oriented Society. New York, Raven Press, 1989, pp 1926. Advances in Pain Research and Therapy; vol 11.
  • 51
    Reuben DB, Mor V, Hiris J: Clinical symptoms and length of survival in patients with terminal cancer. Arch Intern Med 1988; 148: 15861591.
  • 52
    Portenoy RK, Hagen NA: Breakthrough pain: Definition, prevalence and characteristics. Pain 1990; 41: 273281.
  • 53
    Arner S, Meyerson BA: Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 1988; 33: 1123.
  • 54
    Cherny NI, Thaler HT, Friedlander-Klar H, et al: Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms: A combined analysis of controlled, single-dose studies. Neurology 1994; 44: 857861.
  • 55
    Devor M, Basbaum AI, Bennett GJ, et al: Group Report: Mechanisms of neuropathic pain following peripheral injury, in BasbaumAI, BessonJM (eds): Towards a New Pharmacotherapy of Pain. New York, John Wiley & Sons, 1991, pp 417440.
  • 56
    Portenoy RK: Issues in the management of neuropathic pain, in BasbaumAI, BessonJM (eds): Towards a New Pharmacotherapy of Pain. New York, John Wiley & Sons, 1991, pp 393414.
  • 57
    Janig W, Blumberg H, Boas RA, Campbell JN: The reflex sympathetic dystrophy syndrome: Consensus statement and general recommendations for diagnosis and clinical research, in BondMR, CharltonJE, WoolfCJ (eds): Proceedings of the VIth World Congress on Pain. Amsterdam, Elsevier, 1991, pp 373382. Pain Research and Clinical Management; vol 4.
  • 58
    Portenoy RK, Foley KM, Inturrisi CE: The nature of opioid responsiveness and its implications for neuropathic pain: New hypotheses derived from studies of opioid infusions. Pain 1990; 43: 273286.
  • 59
    Dubner R: A call for more science, not more rhetoric, regarding opioids and neuropathic pain. Pain 1991; 47: 12.
  • 60
    Portenoy RK: Adjuvant analgesics in pain management, in DoyleD, HanksGW, MacDonaldN (eds): Oxford Textbook of Palliative Medicine. Oxford, Oxford University Press, 1993, pp 187203.
  • 61
    American Psychiatric Association: Somatoform disorders, in Diagnostic and Statistical Manual of Mental Disorders, ed 3. Washington, DC, American Psychiatric Association, 1987 pp 255267.
  • 62
    World Health Organization: Cancer Pain Relief. Geneva, World Health Organization, 1986
  • 63
    Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971; 231: 232235.
  • 64
    Malmberg AB, Yaksh TL: Hyperalgesia mediated by spinal glutamate and substance P receptor blocked by spinal cyclooxygenase inhibition. Science 1992; 257: 12761279.
  • 65
    Willer JC, De Broucker T, Bussel B, et al: Central analgesic effect of ketoprofen in humans: Electrophysiological evidence for a supraspinal mechanism in a double-blind and cross-over study. Pain 1989; 38: 17.
  • 66
    Piletta P, Porchet HC, Dayer P: Central analgesic effect of acetaminophen but not of aspirin. Clin Pharmacol Ther 1991; 49: 350354.
  • 67
    Brooks PM, Day RO: Nonsteroidal antiinflammatory drugs: Differences and similarities. N Engl J Med 1991; 324: 17161725.
  • 68
    Insel PA: Analgesic-antipyretics and antiinflammatory agents: Drugs employed in the treatment of rheumatoid arthritis and gout, in GilmanAG, RallTW, NiesAS, TeylorP (eds): The Pharmacological Basis of Therapeutics, ed 8. New York, Pergamon Press, 1990, pp 638681.
  • 69
    Seeff LB, Cuccherini BA, Zimmerman HJ, et al: Acetaminophen hepatotoxicity in alcoholics: A therapeutic misadventure. Ann Intern Med 1986; 104: 399404.
  • 70
    Houde RW: Analgesic effectiveness of narcotic agonist-antagonists. Br J Clin Pharmacol 1979; 7: 29753085.
  • 71
    McQuay HJ, Jadad AR, Carroll D, et al: Opioid sensitivity of chronic pain: A patient-controlled analgesia method. Anaesthesia 1992; 47: 757767.
  • 72
    Jadad AR, Carroll D, Glynn CJ, et al: Morphine responsiveness of chronic pain: Double-blind randomised crossover study with patient-controlled analgesia. Lancet 1992; 339: 13671371.
  • 73
    Cherny NI, Thaler HT, Friedlander-Klar H, et al: Opioid responsiveness of neuropathic cancer pain: Combined analysis of single-dose analgesic trials. Proceedings of the American Society of Clinical Oncology 1992; 11: Abstract 1330.
  • 74
    Szeto HH, Inturrisi CE, Houde R, et al: Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure of cancer. Ann Intern Med 1977; 86: 738741.
  • 75
    Eisendrath SJ, Goldman B, Douglas J, et al: Meperidine-induced delirium. Am J Psychiatry 1987; 144: 10621065.
  • 76
    Kaiko RF, Foley KM, Grabinski P, et al: Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol 1983; 13: 180185.
  • 77
    Galer BS, Coyle N, Pasternak GW, Portenoy RK: Individual variability in the response to different opioids: Report of five cases. Pain 1992; 49: 8791.
  • 78
    de Stoutz ND, Bruera E, Suarez-AImazor M: Opiate rotation (OR) for toxicity reduction in terminal cancer patients, in 7th World Congress on Pain: Congress Abstracts. Seattle, IASP Press, 1993, abstract 894.
  • 79
    Crews JC, Sweeney NJ, Denson DD: Clinical efficacy of methadone in patients refractory to other mu-opioid receptor agonist analgesics for management of terminal cancer pain: Case presentations and discussion of incomplete cross-tolerance among opioid agonist analgesics. Cancer 1993; 72: 22662272.
  • 80
    MacDonald N, Der L, Allan S, Champion P: Opioid hyperexcitability: The application of alternate opioid therapy. Pain 1993; 53: 353355.
  • 81
    Chan GL, Matzke GR: Effects of renal insufficiency on the pharmacokinetics and pharmacodynamics of opioid analgesics. Drug Intelligence and Clinical Pharmacology 1987; 21: 773783.
  • 82
    Hagen N, Foley KM, Cerbones DJ, et al: Chronic nausea and morphine-6-glucuronide. Journal of Pain and Symptom Management 1991; 6: 125128.
  • 83
    Osborne RJ, Joel SP, Slevin ML: Morphine intoxication in renal failure: the role of morphine-6-glucuronide. BMJ 1986; 292: 15481549.
  • 84
    Sawe J, Svensson JO, Odar-Cederlof I: Kinetics of morphine in patients with renal failure. Lancet 1985; 2: 211. Letter.
  • 85
    Portenoy RK, Foley KM, Stulman J, et al: Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: Plasma profiles, steady-state concentrations and the consequences of renal failure. Pain 1991; 47: 1319.
  • 86
    McQuay HJ, Carroll D, Faura CC, et al: Oral morphine in cancer pain: Influences on morphine and metabolite concentration. Clin Pharmacol Ther 1990; 48: 236244.
  • 87
    Wilkinson TJ, Robinson BA, Begg EJ, et al: Pharmacokinetics and efficacy of rectal versus oral sustained-release morphine in cancer patients. Cancer Chemother Pharmacol 1992; 31: 251254.
  • 88
    Beaver WT, Feise GA: Comparison of the analgesic effect oxymorphone by rectal suppository and intramuscular injection in patients with postoperative pain. J Clin Pharm 1977; 17: 276291.
  • 89
    Hanning CD: The rectal absorption of opioids, in BenedettiC, ChapmanCR, GironGP (eds): Opioid Analgesia. New York, Raven Press, 1990, pp 259269. Advances in Pain Research and Therapy; vol 14.
  • 90
    Bullingham RE, McQuay HJ, Porter EJ, et al: Sublingual buprenorphine used postoperatively: Ten hour plasma drug concentration analysis. Br J Clin Pharmacol 1982; 13: 665673.
  • 91
    Weinberg DS, Inturrisi CE, Reidenberg B, et al: Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther 1988; 44: 335342.
  • 92
    Portenoy PK, Southam M, Gupta SK, et al: Transdermal fentanyl for cancer pain: Repeated dose pharmacokinetics. Anesthesiology 1993; 78: 3643.
  • 93
    Holley FO, Van-Steennis C: Postoperative analgesia with fentanyl: Pharmacokinetics and pharmacodynamics of constant-rate I.V. and transdermal delivery. Br J Anaesth 1988; 60: 608613.
  • 94
    Gourlay GK, Kowalski SR, Plummer JL, et al: The efficacy of transdermal fentanyl in the treatment of postoperative pain: A double-blind comparison of fentanyl and placebo systems. Pain 1990; 40: 2128.
  • 95
    Coyle N, Cherny NI, Portenoy RK: Subcutaneous opioid infusions in the home. Oncology 1994; 8: 2127.
  • 96
    Bruera E, Brenneis C, Michaud M, et al: Use of the subcutaneous route for the administration of narcotics in patients with cancer pain. Cancer 1988; 62: 407411.
  • 97
    Storey P, Hill CH Jr, St. Louis RH, Tarver EE: Subcutaneous infusions for control of cancer symptoms. Journal of Pain and Symptom Management 1990; 5: 3341.
  • 98
    Portenoy RK: Continuous intravenous infusions of opioid drugs. Med Clin North Am 1987; 71: 233241.
  • 99
    Coyle N, Mauskop A, Maggard J, Foley KM: Continuous subcutaneous infusions of opiates in cancer patients with pain. Oncol Nurs Forum 1986; 13: 5357.
  • 100
    Swanson G, Smith J, Bulich R, et al: Patient-controlled analgesia for chronic cancer pain in the ambulatory setting: A report of 117 patients. J Clin Oncol 1989; 7: 19031908.
  • 101
    Bruera E, Brenneis C, Michaud M, et al: Patient-controlled subcutaneous hydromorphone versus continuous subcutaneous infusion for the treatment of cancer pain. J Natl Cancer Inst 1988; 80: 11521154.
  • 102
    Bruera E, Macmillan K, Selmser P, MacDonald RN: Decreased local toxicity with subcutaneous diamorphine (heroin): A preliminary report. Pain 1990; 43: 9194.
  • 103
    Moulin DE, Kreeft JH, Murray-Parsons N, Bouquillon AI: Comparison of continuous subcutaneous and intravenous hydromorphone infusions for management of cancer pain. Lancet 1991; 337: 465468.
  • 104
    Moulin DE, Johnson NG, Murray-Parsons N, et al: Subcutaneous narcotic infusions for cancer pain: Treatment outcome and guidelines for use. Can Med Assoc J 1992; 146 (6): 891897.
  • 105
    Bruera E, Fainsinger R, Moore M, et al: Local toxicity with subcutaneous methadone: Experience of two centers. Pain 1991; 45: 141143.
  • 106
    Waldmann CS, Eason JR, Rambohul E, Hanson GC: Serum morphine levels: A comparison between continuous subcutaneous infusion and continuous intravenous infusion in postoperative patients. Anaesthesia 1984; 39: 768771.
  • 107
    Dover SB: Syringe driver in terminal care. BMJ 1987; 294: 553555.
  • 108
    Amesbury BDW: Use of SC Midazolam in the home care setting. Palliative Medicine 1989; 3: 299301.
  • 109
    Oliver DJ: Syringe drivers in palliative care: A review. Palliative Medicine 1988; 2: 2126.
  • 110
    Fainsinger R, Schoeller T, Bruera E: Methadone in the management of cancer pain: A review. Pain 1993; 52: 137147.
  • 111
    Grochow L, Sheidler V, Grossman S, et al: Does intravenous methadone provide longer lasting analgesia than intravenous morphine? A randomized double-blind study. Pain 1989; 38: 151157.
  • 112
    Arkinstall WW, Goughnour BR, White JA, Stewart JH: Control of severe pain with sustained-release morphine tablets v. oral morphine solution. Can Med Assoc J 1989; 140: 653657, 661.
  • 113
    Bruera E, Sloan P, Scott J, Mount B: Slow release (SR) versus intermediate release (IR) hydromorphone (HM) in patients with cancer pain: A controlled, crossover trial, in 7th World Congress on Pain: Congress Abstracts. Seattle, IASP Press, 1993, abstract 899.
  • 114
    Hagen N, Dhaliwal H, Hays H, et al: Crossover evaluation of the clinical efficacy and safety of controlled (cr) and immediate release (ir) hydromorphone in cancer pain, in 7th World Congress on Pain: Congress Abstracts. Seattle, IASP Press, 1993, abstract 898.
  • 115
    Shepard K: Review of a controlled-release morphine preparation, in FoleyKM, BonicaJJ, VentafriddaV (eds): Second International Congress on Cancer Pain. New York, Raven Press, 1990, pp 191202. Advances in Pain Research and Therapy; vol 16.
  • 116
    Citron ML, Kalra JM, Seltzer VL, et al: Patient-controlled analgesia for cancer pain: A long-term study of inpatient and outpatient use. Cancer Invest 1992; 10: 335341.
  • 117
    Brescia FJ, Portenoy RK, Ryan M, et al: Pain, opioid use, and survival in hospitalized patients with advanced cancer. J Clin Oncol 1992; 10: 149155.
  • 118
    Kanner RM, Foley KM: Patterns of narcotic drug use in a cancer pain clinic. Ann NY Acad Sci 1981; 362: 161172.
  • 119
    Edwards WT, Breed RJ: The treatment of postoperative pain in the postanesthesia care unit. Anesthesiology Clinics of North America 1990; 8: 235265.
  • 120
    Coyle N, Adelhardt J, Foley KM: Disease progression and tolerance in the cancer pain patient: 2nd International Congress on Cancer Pain. Journal of Pain and Symptom Management 1988; 3: S25.
  • 121
    Coyle N, Breitbart W, Weaver S, Portenoy RK: Delerium as a contributing factor to crecendo pain: three case reports. Journal of Pain and Symptom Management 1994; 9 (1): 4447.
  • 122
    Sykes NP: Constipation and diarrhoea, in DoyleD, HanksGW, MacDonaldN (eds): Oxford Textbook of Palliative Medicine. Oxford, Oxford University Press, 1993, pp 299310.
  • 123
    Sykes NP: Oral naloxone in opioid-associated constipation. Lancet 1991; 337: 1475.
  • 124
    Culpepper-Morgan JA, Inturrisi CE, Portenoy RK, et al: Treatment of opioid-induced constipation with oral naloxone: A pilot study. Clin Pharmacol Ther 1992; 52: 9095.
  • 125
    Campora E, Merlini L, Pace M, et al: The incidence of narcotic-induced emesis. Journal of Pain and Symptom Management 1991; 6: 428430.
  • 126
    Bruera E, Macmillan K, Hanson J, MacDonald RN: The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain 1989; 39: 1316.
  • 127
    Eisele JH Jr Grigsby EJ, Dea G: Clonazepam treatment of myoclonic contractions associated with high-dose opioids: A case report. Pain 1992; 49: 231232.
  • 128
    Foley KM: Clinical tolerance to opioids, in BasbaumAI, BessomJM (eds): Towards a New Pharmacotherapy of Pain, Dahlem Konfrenzen. New York, John Wiley & Sons, 1991, pp 181204.
  • 129
    Goldfrank L, Weisman RS, Errick JK, Lo MW: A dosing nomogram for continuous infusion of intravenous naloxone. Ann Emerg Med 1986; 15: 566570.
  • 130
    Bradberry JC, Raebel MA: Continuous infusion of naloxone in the treatment of narcotic overdose. Drug Intelligence and Clinical Pharmacy 1981; 15: 945950.
  • 131
    Schuster CR: Does treatment of cancer pain with narcotics produce junkies? in HillCSJr, FieldsWS (eds): Drug Treatment of Cancer Pain in a Drug-Oriented Society. New York, Raven Press, 1989, pp 13. Advances in Pain Research and Therapy; vol 11.
  • 132
    Foley KM: The decriminalization of cancer pain. In: HillCSJr, FieldsWS (eds): Drug Treatment of Cancer Pain in a Drug-Oriented Society. New York, Raven Press, 1989, pp 518. Advances in Pain Research and Therapy; vol 11.
  • 133
    Chapman CR, Hill HF: Prolonged morphine self-administration and addiction liability: Evaluation of two theories in a bone marrow marrow transplant unit. Cancer 1989; 63: 16361644.
  • 134
    Porter J, Jick H: Addiction rare in patients treated with narcotics. N Engl J Med 1980; 302: 123. Letter.
  • 135
    American College of Physicians Health and Public Policy Committee: Drug therapy for severe chronic pain in terminal illness. Ann Intern Med 1983; 99: 870873.
  • 136
    American Pain Society: Principles of Analgesic Use in the Treatment Acute Pain and Chronic Cancer Pain: A Concise Guide to Medical Practice, ed 3. Skokie, Ill, American Pain Society, 1992.
  • 137
    Weissman DE, Haddox JD: Opioid pseudoad-diction: An iatrogenic syndrome. Pain 1989; 36: 363366.
  • 138
    Ettinger AB, Portenoy RK: The use of corticosteroids in the treatment of symptoms associated with cancer. Journal of Pain and Symptom Management 1988; 3: 99103.
  • 139
    Della Cuna GR, Pellegrini A, Piazzi M: Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients. A placebo-controlled multicenter study. European Journal of Cancer and Clinical Oncology 1989; 25: 18171821.
  • 140
    Tannock I, Gospodarowicz M, Meakin W, et al: Treatment of metastatic prostatic cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 1989; 7: 590597.
  • 141
    Popiela T, Lucchi R, Giongo F: Methylprednisolone as palliative therapy for female terminal cancer patients: The Methylprednisolone Female Preterminal Cancer Study Group. European Journal of Cancer and Clinical Oncology 1989; 25: 18231829.
  • 142
    Moertel CG, Shutt AJ, Reitemeier R, Hahn RG: Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 1974; 33: 16071609.
  • 143
    Willox JC, Corr J, Shaw J, et al: Prednisolone as appetite stimulant in patients with cancer. BMJ 1984; 288: 27.
  • 144
    Bruera E, Roca E, Cedaro L, et al: Action of oral methylprednisolone in terminal cancer patients: A prospective randomized double-blind study. Cancer Treatment Report 1985; 69: 751754.
  • 145
    Wig J, Johl KS: Our experience with EMLA Cream (for painless venous cannulation in children). Indian J Physiol Pharmacol 1990; 34: 130132.
  • 146
    Halperin DL, Koren G, Attias D, et al: Topical skin anesthesia for venous, subcutaneous drug reservoir and lumbar punctures in children. Pediatrics 1989; 84: 281284.
  • 147
    Soliman IE, Broadman LM, Hannallah RS, McGill WA: Comparison of the analgesic effects of EMLA (eutectic mixture of local anesthetics) to intradermal lidocaine infiltration prior to venous cannulation in unpremedicated children. Anesthesiology 1988; 68: 804806.
  • 148
    Cooper CM, Gerrish SP, Hardwick M, Kay R: EMLA cream reduces the pain of venepuncture in children. Eur J Anaesthesiol 1987; 4: 441448.
  • 149
    Maunuksela EL, Korpela R: Double-blind evaluation of a lignocaine-prilocaine cream (EMLA) in children: Effect on the pain associated with venous cannulation. Br J Anaesth 1986; 58: 12421245.
  • 150
    Kapelushnik J, Koren G, Solh H, et al: Evaluating the efficacy of EMLA in alleviating pain associated with lumbar puncture: Comparison of open and double-blinded protocols in children. Pain 1990; 42: 3134.
  • 151
    Nilsson A, Danielson K, Engberg G, Henneberg S: EMLA for pain relief during arterial cannulation: A double-blind, placebo-controlled study of a lidocaine-prilocaine cream. Ups J Med Sci 1990; 95: 8794.
  • 152
    Shortsleeve MJ, Levine MS: Herpes esophagitis in otherwise healthy patients: Clinical and radiographic findings. Radiology 1992; 182: 859861.
  • 153
    Carnel SB, Blakeslee DB, Oswald SG, Barnes M: Treatment of radiation- and chemotherapy-induced stomatitis. Otolaryngol Head Neck Surg 1990; 102: 326330.
  • 154
    Watts SJ, Alexander LC, Fawcett K, et al: Herpes simplex esophagitis in a renal transplant patient treated with cyclosporine A: A case report. Am J Gastroenterol 1986; 81: 185188.
  • 155
    Welling LR, Watson WA: The emergency department treatment of dyspepsia with antacids and oral lidocaine. Ann Emerg Med 1990; 19: 785788.
  • 156
    Berkey CS, Eisenberg E, Carr DB, Chalmers TC, Mosteller F: Nonsteroidal anti-inflammatory drugs (NSAIDS) for cancer pain: Meta-analysis, in 7th World Congress on Pain: Abstracts. Seattle, IASP Press, 1993, abstract 5.
  • 157
    Robinson RG, Preston DF, Spicer JA, Baxter KG: Radionuclide therapy of intractable bone pain: Emphasis on strontium-89. Semin Nucl Med 1992; 22: 2832.
  • 158
    Porter AT, McEwan AJ, Powe JE, et al: Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993; 25: 805813.
  • 159
    Lewington VJ, McEwan AJ, Ackery DM, et al: A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 1991; 27 (8): 954958.
  • 160
    Laing AH, Ackery DM, Bayly RJ, et al: Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol 1991; 64: 816822.
  • 161
    Fossa SD, Paus E, Lochoff M, et al: Strontium-89 in bone metastases from hormone resistant prostate cancer: Palliation effect and biochemical changes. Br J Cancer 1992; 66: 177180.
  • 162
    Dearnaley DP, Bayly RJ, A'Hern RP, et al: Palliation of bone metastases in prostate cancer: Hemibody irradiation or strontium-89?. Clin Oncol (R Coll Radiol) 1992; 4: 101107.
  • 163
    Turner JH, Claringbold PG, Hetherington EL, et al: A phase 1 study of samarium-153 ethylenediamenetetramethylene phosphonate therapy for disseminated skeletal metastases. J Clin Oncol 1989; 7: 19261931.
  • 164
    Turner JH, Claringbold PG: A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate. Eur J Cancer 1991; 27: 10841086.
  • 165
    Maxon HR, Deutsch EA, Thomas SR, et al: Initial experience with 186-Re(Sn)-HEDP in the treatment of painful skeletal metastases. J Nucl Med 1988; 29: 776.
  • 166
    Maxon HR 3rd, Thomas SR, Hertzberg VS, et al: Rhenium-186 hydroxyethylidene diphosphonate for the treatment of painful osseous metastases. Semin Nucl Med 1992; 22: 3340.
  • 167
    Coleman RE, Woll PJ, Miles M, et al: Treatment of bone metastases from breast cancer with (3 amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Br J Cancer 1988; 58: 621625.
  • 168
    Thiebaud D, Leyvraz S, von Fliedner V, et al: Treatment of bone metastases from breast cancer and myeloma with pamidronate. Eur J Cancer 1991; 27: 3741.
  • 169
    Morton AR, Cantrill JA, Pillai GV, et al: Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma. BMJ 1988; 297: 772773.
  • 170
    van Holten-Verzantvoort AT, Zwinderman AH, Aaronson NK, et al: The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. Eur J Cancer 1991; 27: 544549.
  • 171
    Ernst DS, MacDonald RN, Paterson AH, et al: A double-blind, crossover trial of intravenous clodronate in metastatic bone pain. Journal of Pain and Symptom Management 1992; 7: 411.
  • 172
    Clemens MR, Fessele K, Heim ME: Multiple myeloma: Effect of daily dichloromethylene bisphosphonate on skeletal complications. Ann Hematol 1993; 66 (3): 141146.
  • 173
    van Holten-Verzantvoort AT, Kroon HM, Bijvoet OL, et al: Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 491498.
  • 174
    Roth A, Kolaric K: Analgesic activity of calcitonin in patients with painful osteolytic metastases of breast cancer: Results of a controlled randomized study. Oncology 1986; 43: 283287.
  • 175
    Warrell RP Jr Lovett D, Dilmanian FA, et al: Low-dose gallium nitrate for prevention of osteolysis in myeloma: Results of a pilot randomized study. J Clin Oncol 1993; 11: 24432450.
  • 176
    Abrams PH, Fenely RC: The actions of prostaglandins on the smooth muscle of the human urinary tract in vitro. Br J Urology 1975; 47: 909915.
  • 177
    Cardozo LD, Stanton SL: A comparison between bromocriptine and indomethacin in the treatment of detrusor instability. J Urology 1980; 123: 399401.
  • 178
    Hanks GW, Portenoy RK, MacDonald N, O'Niel WM: Difficult pain problems, in DoyleD, HanksGW, MacDonaldN (eds): Oxford Textbook of Palliative Medicine. Oxford, Oxford University Press, 1993, pp 257274.
  • 179
    Castell DO: Calcium blocking agents for gastrointestinal disorders. Am J Cardiol 1985; 55:210B–213B.
  • 180
    Twycross RG, Lack SA: Therapeutics in Terminal Cancer, ed 2. Edinburgh, Churchill Livingston, 1990.
  • 181
    Hanks GW. Psychotropic drugs. Clinics in Oncology 1984; 3: 135151.
  • 182
    Ventafridda V, Ripamonti C, Caraceni A, et al: The management of inoperable gastrointestinal obstruction in terminal cancer patients. Tumori 1990; 76: 389393.
  • 183
    Baines M: The pathophysiology and management of maliganant intestinal obstruction, in DoyleD, HanksGW, MacDonaldN (eds): Oxford Textbook of Palliative Medicine. Oxford, Oxford University Press, 1993, pp 311316.
  • 184
    De Conno F, Caraceni A, Zecca E, et al: Continuous subcutaneous infusion of hyoscine butylbromide reduces secretions in patients with gastrointestinal obstruction. Journal of Pain and Symptom Management 1991; 6: 484486.
  • 185
    Baines MJ: Management of malignant intestinal obstruction in patients with advanced cancer, in FoleyKM, BonicaJJ, VentafriddaV (eds): Second International Congress on Cancer Pain. New York, Raven Press, 1990, pp 327335. Advances in Pain Research and Therapy; vol 16.
  • 186
    Syversen JH, Mollestad E, Semb LS: Emepronium bromide (Cetiprin) as a postoperative spasmolytic agent in transvesical prostatectomy. Scand J Urol Nephrol 1976; 10: 201203.
  • 187
    Bradley DV, Cazort RJ: Relief of bladder spasm by flavoxate: A comparative study. J Clin Pharmacol J New Drugs 1970; 10: 6568.
  • 188
    Canobbio L, Boccardo F, Cannata D, et al: Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014: Preliminary results of a pilot study. Cancer 1992; 69: 648650.
  • 189
    Ihse I, Permerth J: Enzyme therapy and pancreatic pain. Acta Chir Scand 1990; 156: 281283.
  • 190
    Fishman B: The treatment of suffering in patients with cancer pain: Cognitive-behavioral approaches, in FoleyKM, BonicaJJ, VentafriddaV (eds): Second International Congress on Cancer Pain. New York, Raven Press, 1990, pp 301316. Advances in Pain Research and Therapy; vol 16.
  • 191
    Turk D, Meichenbaum D, Genest M: Pain and Behavioral Medicine. New York, Guilford Press, 1983.
  • 192
    Linton SL, Melin L: Applied relaxation in the management of cancer pain. Behavioral Psychotherapy 1983; 11: 337350.
  • 193
    Fordyce WE: Behavioral Methods for Chronic Pain and Illness. St. Louis: CV Mosby, 1976.
  • 194
    Rhiner M, Ferrell BR, Ferrell BA, Grant MM: A structured nondrug intervention program for cancer pain. Cancer Practice 1993; 1: 137143.
  • 195
    Brennan MJ: Lymphedema following the surgical treatment of breast cancer: A review of pathophysiology and treatment. Journal of Pain and Symptom Management 1992; 7: 110116.
  • 196
    Plummer JL, Cherry DA, Cousins MJ, et al: Long term spinal administration of morphine in cancer and non-cancer pain: A retrospective study. Pain 1991; 44: 215220.
  • 197
    Hogan Q, Haddox JD, Abram S, et al: Epidural opiates and local anesthetics for the management of cancer pain. Pain 1991; 46: 271279.
  • 198
    Moulin DE, Inturrisi CE, Foley KM: Epidural and intrathecal opioids: Cerebrospinal fluid and plasma pharmacokinetics in cancer pain patients, in FoleyKM, InturrisiCE (eds): Opioid Analgesics in the Management of Clinical Pain. New York, Raven Press, 1986, pp 369383. Advances in Pain Research and Therapy; vol 8.
  • 199
    Max MB, Inturrisi CE, Kaiko RF, et al: Epidural and intrathecal opiates: Cerebrospinal fluid and plasma profiles in patients with chronic cancer pain. Clin Pharmacol Ther 1985; 38: 631641.
  • 200
    Brose WG, Tanelian DL, Brodsky JB, et al: CSF and blood pharmacokinetics of hydromorphone and morphine following lumbar epidural administration. Pain 1991; 45: 1115.
  • 201
    Chrubasik J, Wust H, Schulte-Monting J, et al: Relative analgesic potency of epidural fentanyl, alfentanil, and morphine in treatment of postoperative pain. Anesthesiology 1988; 68: 929933.
  • 202
    DuPen SL, Ramsey DH: Compounding local anaesthetics and narcotics for epidural analgesia in cancer out-patients. Anesthesiology 1988; 69: A405.
  • 203
    Nitescu P, Appelgren L, Linder LE, et al: Epidural versus intrathecal morphine-bupivacaine: Assessment of consecutive treatments in advanced cancer pain. Journal of Pain and Symptom Management 1990; 5: 1826.
  • 204
    Sjoberg M, Appelgren L, Einarsson S, et al: Long-term intrathecal morphine and bupivacaine in refractory cancer pain: I. Results from the first series of 52 patients. Acta Anaesthesiol Scand 1991; 35: 3043.
  • 205
    Obbens EA, Hill CS, Leavens ME, et al: Intraventricular morphine administration for control of chronic cancer pain. Pain 1987; 28: 6168.
  • 206
    Lobato RD, Madrid JL, Fatela LV, et al: Intraventricular morphine for intractable cancer pain: Rationale, methods, clinical results. Acta Anaesthesiol Scand Suppl 1987; 85: 6874.
  • 207
    Leavens ME, Hill CS Jr Cech DA, et al: Intrathecal and intraventricular morphine for pain in cancer patients: Initial study. J Neurosurgery 1982; 56: 241245.
  • 208
    Lee TL, Kumar A, Baratham G: Intraventricular morphine for intractable craniofacial pain. Singapore Med J 1990; 31: 273276.
  • 209
    Nurchi G: Use of intraventricular and intrathecal morphine in intractable pain associated with cancer. Neurosurgery 1984; 15: 801803.
  • 210
    Roquefeuil B, Benezech J, Blanchet P, et al: Intraventricular administration of morphine in patients with neoplastic intractable pain. Surg Neurol 1984; 21: 155158.
  • 211
    Crammond T, Stuart G: Intraventricular morphine for intractable pain of advanced cancer. Journal of Pain and Symptom Management 1993; 8: 465473.
  • 212
    Dennis GC, DeWitty RL: Long-term itraventricular infusion of morphine for intractable pain in cancer of the head and neck. Neurosurgery 1990; 26: 404407.
  • 213
    Fineman SP: Long-term post-thoracotomy cancer pain management with interpleural bupivacaine. Anesth Analg 1989; 68: 694697.
  • 214
    Myers DP, Lema MJ, de Leon-Casasola OA, Bacon DR: Interpleural analgesia for the treatment of severe cancer pain in terminally ill patients. Journal of Pain and Symptom Management 1993; 8: 505510.
  • 215
    Lema MJ, Myers DP, de Leon-Casasola OA, Penetrante R: Pleural phenol therapy for the treatment of chronic esophageal cancer pain. Reg Anesth 1992; 17: 166170.
  • 216
    Waldman SD, Allen ML, Cronen MC: Subcutaneous tunneled intrapleural catheters in the long-term relief of right upper quadrant pain of malignant origin. Journal of Pain and Symptom Management 1989; 4: 8689.
  • 217
    Brown DL, Bulley CK, Quiel EL: Neurolytic celiac plexus block for pancreatic cancer pain. Anesth Anal 1987; 66: 869873.
  • 218
    Cousins MJ, Dwyer B, Gibb D: Chronic pain and neurolytic neural blockade, in CousinsMJ, BridenbaughPO (eds): Neural Blockade in Clinical Anesthesia and Management of Pain, ed 2. Philadelphia, JB Lippincott, 1988, pp 10531084.
  • 219
    Bonica JJ, Buckley FP, Moricca G, Murphy TM: Neurolytic blockade and hypophysectomy, in BonicaJJ (ed): The Management of Pain, ed 2. Philadelphia, Lea & Febiger, 1990, pp 19802039. vol 2.
  • 220
    Mercadante S: Celiac plexus block versus analgesics in pancreatic cancer pain. Pain 1993; 52: 187192.
  • 221
    Lillemoe KD, Cameron JL, Kaufman HS, et al: Chemical splanchnicectomy in patients with unresectable pancreatic cancer: A prospective randomized trial. Ann Surg 1993; 217: 447455.
  • 222
    Hellendoorn-Smit M, Overweg-van Kints J: Perineal pain: A case report. Eur J Surg Oncol 1988; 14: 197198.
  • 223
    Ischia S, Luzzani A, Ischia A, et al: Subarachnoid neurolytic block (L5–S1) and unilateral percutaneous cervical cordotomy in the treatment of pain secondary to pelvic malignant disease. Pain 1984; 20: 139149.
  • 224
    Sindou M, Fisher G, Mansuy L: Posterior spinal rhizotomy and selective posterior rhizidiotomy. Progress in Neurosurgical Surgery 1976; 7: 201250.
  • 225
    Robertson DH: Transsacral neurolytic nerve block: An alternative approach to intractable perineal pain. Br J Anaesth 1983; 55: 873875.
  • 226
    Arbit E: Neurosurgical management of cancer pain, in FoleyKM, BonicaJJ, VentafridaV (eds): Second International Congress on Cancer Pain. New York, Raven Press, 1990, pp 289300. Advances in Pain Research and Therapy; vol 16.
  • 227
    Rosomoff HL, Brown CJ, Sheptak P: Percutaneous radiofrequency cervical cordotomy: Technique. J Neurosurg 1965; 23: 639644.
  • 228
    Stuart G, Cramond T: Role of percutaneous cervical cordotomy for pain of malignant origin. Med J Aust 1993; 158: 667670.
  • 229
    Tasker RR: Percutaneous cordotomy: The lateral high cervical technique, in SchmidekHH, SweetWH (eds): Operative Neurosurgical Technique Indications, Methods and Results. New York, Grune and Stratton, 1988: pp 11911205.
  • 230
    Polatty RC, Cooper KR: Respiratory failure after percutaneous cordotomy. South Med J 1986; 79: 897899.
  • 231
    Levin AB, Ramirez LL: Treatment of cancer pain with hypophysectomy: Surgical and chemical, in BenedettiC, ChapmanCR, MoriccaG (eds): Recent Advances in the Management of Pain. New York, Raven Press, 1984, 631645. Advances in Pain Research and Therapy; vol 7.
  • 232
    Hassenbusch SJ, Pillay PK, Barnett GH: Radiofrequency cingulotomy for intractable cancer pain using stereotaxis guided by magnetic resonance imaging. Neurosurgery 1990; 27: 220223.
  • 233
    Greene WR, Davis WH: Titrated intravenous barbiturates in the control of symptoms in patients with terminal cancer. South Med J 1991; 84: 332337.
  • 234
    Truog RD, Berde CB, Mitchell C, Greir HE: Barbiturates in the care of the terminally ill. N Engl J Med 1992; 327: 16781682.
  • 235
    Enck RE: Drug-induced terminal sedation for symptom control. American Journal of Hospital Palliative Care 1991; 8: 35.
  • 236
    Cherny NI, Portenoy RK: Sedation in the treatment of refractory symptoms: Guidelines for evaluation and treatment. J Palliat Care 1994; 10: 3138.
  • 237
    Burke AL, Diamond PL, Hulbert J, et al: Terminal restlessness: Its management and the role of midazolam. Med J Aust 1991; 155: 485487.
  • 238
    Smales OR, Smales EA, Sanders HG: Flunitrazepam in terminal care. J Paediatr Child Health 1993; 29: 6869.
  • 239
    Roy DJ: Need they sleep before they die?. J Palliat Care 1990; 6: 34. Editorial.
  • 240
    Mount B: A final crecendo of pain?. J Palliat Care 1990; 6: 56.
  • 241
    Lichter I, Hunt E: The last 48 hours of life. J Palliat Care 1990; 6: 715.
  • 242
    Latimer EJ: Ethical decision-making in the care of the dying and its applications to clinical practice. Journal of Pain and Symptom Management 1991; 6: 329336.
  • 243
    Edwards RB: Pain management and the values of health care providers, in HillCSJr, FieldsWS (eds): Drug Treatment of Cancer Pain in a Drug-Oriented Society. New York, Raven Press, 1989, pp 101112. Advances in Pain Research and Therapy; vol 11.
  • 244
    Wanzer SH, Federman DD, Adelstein SJ, et al: The physician's responsibility toward hopelessly ill patients: A second look. N Engl J Med 1989; 320: 844849.
  • 245
    Martin RS: Mortal values: Healing, pain and suffering, in HillCSJr, FieldsWS (eds): Drug Treatment of Cancer Pain in a Drug-Oriented Society. New York, Raven Press, 1989, pp 1926. Advances in Pain Research and Therapy; vol 11.